化疗诱导的周围神经病变:当前综述
本文综述了化疗诱导的周围神经病变(CIPN)的临床表型与病理机制。约30%至40%接受神经毒性化疗的患者会发生CIPN,以感觉为主并伴疼痛,可导致幸存者长期病残。随着癌症生存率提高,CIPN晚期效应的患病率和负担可能增加。
要点
- 约30%至40%接受神经毒性化疗的患者会发生CIPN。
- CIPN常以感觉为主并伴疼痛,可致长期病残。
- 癌症生存率改善可能增加CIPN晚期效应的负担。
核心结论
- CIPN是癌症治疗中常见的剂量限制性副作用,以感觉为主并伴疼痛,可导致幸存者长期病残。
研究设计与样本
- 综述,讨论癌症患者周围神经病变的评估方法及特定神经毒性化疗药的临床表型和病理机制。
主要发现
- 约30%至40%接受神经毒性化疗的患者会发生CIPN,严重程度在患者间差异很大。
- CIPN常以感觉为主并伴疼痛,可导致幸存者长期病残。
- 随着癌症生存率持续改善,CIPN晚期效应的患病率和负担可能增加。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chemotherapy-induced peripheral neuropathy (CIPN) is a common dose-limiting side effect experienced by patients receiving treatment for cancer. Approximately 30 to 40% of patients treated with neurotoxic chemotherapy will develop CIPN, and there is considerable variability in its severity between patients. It is often sensory-predominant with pain and can lead to long-term morbidity in survivors. The prevalence and burden of CIPN late effects will likely increase as cancer survival rates continue to improve. In this review, we discuss the approach to peripheral neuropathy in patients with cancer and address the clinical phenotypes and pathomechanisms of specific neurotoxic chemotherapeutic agents. Ann Neurol 2017;81:772-781.
引用
- Staff NP, Grisold A, Grisold W, et al. Chemotherapy-induced peripheral neuropathy: A current review. Ann Neurol. 2017. PMID: 28486769. doi:10.1002/ana.24951
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。